Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Update on viral hepatitis: 2006.

Jessica Tan1, Anna Sf Lok

  • 1Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan 48109-0362, USA.

Current Opinion in Gastroenterology
|April 7, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

National trends in general surgical trainees' operative numbers (2013-2022).

The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland·2026
Same author

Exploring the information needs of breast cancer patients and families in a large, urban, academic hospital: perceived barriers and facilitators to finding relevant and credible information.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Elimination of chronic viral hepatitis C in correctional health.

Singapore medical journal·2025
Same author

Assessing how a teaching professional development program for biology graduate students bolsters self-efficacy and shapes teaching perspectives.

Journal of microbiology & biology education·2025
Same author

A study of MD-PhD pre-health advising identifies challenges to building a robust MD-PhD applicant pool.

JCI insight·2025
Same author

Correction for Ramos et al., "Broadly protective bispecific antibodies that simultaneously target influenza virus hemagglutinin and neuraminidase".

mBio·2025
Same journal

Endoscopic techniques to minimize gastroesophageal reflux during peroral endoscopic myotomy.

Current opinion in gastroenterology·2026
Same journal

Postendoscopy esophageal adenocarcinoma and neoplasia: current status and future directions.

Current opinion in gastroenterology·2026
Same journal

The complement system in inflammatory bowel disease: from early observations to emerging frontiers.

Current opinion in gastroenterology·2026
Same journal

Goblet cell-associated antigen passages in health and disease.

Current opinion in gastroenterology·2026
Same journal

Inflammatory bowel diseases 2026: form, function and therapeutic considerations for the epithelial barrier.

Current opinion in gastroenterology·2026
Same journal

Dietary protein as a regulator of colitis and colorectal cancer.

Current opinion in gastroenterology·2026
See all related articles

Recent viral hepatitis research highlights increased cirrhosis and cancer risk with high hepatitis B virus DNA. New treatments offer promise, but long-term therapy risks drug resistance.

Area of Science:

  • Hepatology
  • Virology
  • Gastroenterology

Background:

  • Viral hepatitis remains a significant global health concern.
  • Ongoing research aims to improve treatment efficacy and patient outcomes.

Purpose of the Study:

  • To review recent advancements in viral hepatitis management.
  • To summarize key findings from publications between December 2005 and November 2006.

Main Methods:

  • Literature review of publications on viral hepatitis.
  • Analysis of treatment outcomes and risk factors.

Main Results:

  • Elevated hepatitis B virus DNA in middle-aged individuals with perinatal infection correlates with higher cirrhosis and hepatocellular carcinoma risk.

Related Experiment Videos

  • Entecavir is effective for nucleoside-naïve patients with chronic hepatitis B.
  • For lamivudine-resistant hepatitis B, adding adefovir to lamivudine or considering tenofovir is recommended.
  • Shorter treatment durations may suffice for genotype 2 hepatitis C with pegylated interferon and ribavirin.
  • Pegylated interferon monotherapy is effective for hepatitis D, with no added benefit from ribavirin.

    • Conclusions:

    • Recent developments allow for refined viral hepatitis treatment strategies.
    • Balancing treatment benefits against the risk of drug-resistant mutations is crucial for long-term therapy.